Attachment A - Price Schedule.xlsx
XLSX spreadsheet 58 KB Posted
- Attached to
- Q301--Reference Lab Testing
- Solicitation number
- 36C26226Q0973
About this file
This is a Price Schedule attachment for a Department of Veterans Affairs Indefinite-Delivery Indefinite-Quantity (IDIQ) contract solicitation (36C26226Q0973) for reference laboratory testing services. The schedule lists 148 laboratory line items across a Base Year and four Option Years, with estimated annual quantities for each service. Services span multiple diagnostic categories including cytogenetics (interphases, metaphases, FISH probes), immunohistochemistry stains (IHC, ISH, IF), hematologic and molecular testing (BCR/ABL mutations, JAK2 mutations, flow cytometry), next-generation sequencing panels (melanoma, solid tumors, myeloid neoplasms), and specialized assays (thrombophilia profiles, autoimmune/paraneoplastic evaluations, immunosuppressive drug monitoring). Line items are coded with Current Procedural Terminology (CPT) codes and include quantity estimates ranging from 2 to 700 tests annually per line item, with provisions for identifying the performing laboratory's CLIA certification number and location.
The pricing template requires bidders to complete unit prices and extended prices for all 148 services across the Base Year and four Option Years, with a total pricing line at the conclusion of each contract period. Bidders must also provide company information including firm name, address, telephone number, email, point of contact, and UEI number. The contract is issued under FAR Part 12 for commercial items with a NAICS code 621511 (medical laboratories) and a size standard of $41.5 million, targeting Firm-Fixed Price delivery of laboratory services through full and open competition.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Amendment 0001.docx | DOCX document | |
| 36C26226Q0973 0001.docx | DOCX document | |
| Attachment B - SOW.doc | DOC document | |
| 36C26226Q0973.docx | DOCX document |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
1. Base
| CLIN | Service | CPT Code | Estimated Annual Quantity | Base Year Unit Price | Extended Price | Name of Lab Performing Test | Location (City, State) of Lab Performing Test | CLIA Certification Number of Lab Performing Test |
| 1 | Interphases, >=100 (Bill Only) | 88275 | 30 | $ - 0 | ||||
| 2 | Metaphases, 15-20 (Bill Only) | 88262 | 2 | $ - 0 | ||||
| 3 | Metaphases, 20-25 (Bill Only) | 88264 | 36 | $ - 0 | ||||
| 4 | Metaphases, 1-19 (Bill Only) | 88264 | 2 | $ - 0 | ||||
| 5 | Probe, +1 (Bill Only) | 88271 | 2 | $ - 0 | ||||
| 6 | Probe, +2 (Bill Only) | 88271x2 | 26 | $ - 0 | ||||
| 7 | Probe, Each Additional (BLYM) (Bill Only) | 88377 | 2 | $ - 0 | ||||
| 8 | Probe, Each Additional (SLL) (Bill Only) | 88377 | 20 | $ - 0 | ||||
| 9 | Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual | 88360 | 34 | $ - 0 | ||||
| 10 | 25-Hydroxyvitamin D:24,25-Dihydroxyvitamin D Ratio, Serum | 82306, 82542 | 2 | $ - 0 | ||||
| 11 | 3-Methoxytyramine, 24 Hour, Urine | 82542 | 2 | $ - 0 | ||||
| 12 | Thrombophilia Profile, Plasma and Whole Blood | 81240, |
85300, 85303, 85306, 85307, 85379, 85384, 85390, 85610, 85613,
| 85670, 85730 | 2 | $ - 0 | ||||
| 13 | Adalimumab Quantitative with Reflex to Antibody, Serum | 80145 | 74 | $ - 0 | ||
| 14 | Flow Cytometry, Cell Surface, Additional | 88185 | 700 | $ - 0 | ||
| 15 | Adrenocorticotropic Hormone (ACTH), Plasma | 82024 | 370 | $ - 0 | ||
| 16 | Acute Myeloid Leukemia (AML), Specified FISH, Varies | 88271x2, 88275x 88291 | 2 | $ - 0 | ||
| 17 | Adalimumab Antibody, Serum | 83520 | 32 | $ - 0 | ||
| 18 | Amylase, Pancreatic Cyst | 82150 | 10 | $ - 0 | ||
| 19 | Amyloid Protein Identification, Paraffin, LC-MS/MS | 88313 | 6 | $ - 0 | ||
| 20 | APOL1 Genotype, Varies | 81479 | 6 | $ - 0 | ||
| 21 | Alpha-Globin Gene Analysis | 81269 | 2 | $ - 0 | ||
| 22 | Antithrombin Antigen, Plasma | 85301 | 2 | $ - 0 | ||
| 23 | BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR, Quantitative, Monitoring Assay, Varies | 81207 | 2 | $ - 0 | ||
| 24 | BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay | 81206 81208 | 6 | $ - 0 | ||
| 25 | BCR/ABL, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing | 81170 | 2 | $ - 0 | ||
| 26 | B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), Specified FISH, Varies | 88271x2, 88275, 88291 | 2 | $ - 0 | ||
| 27 | Immunoglobulin Gene Rearrangement, Varies | 81261, 81264 | 22 | $ - 0 | ||
| 28 | IGH for B-Cell Chronic Lymphocytic Leukemia (B-CLL), Somatic Hypermutation Analysis | 81263 | 2 | $ - 0 | ||
| 29 | BCR/ABL1, p210, mRNA Detection, RT-PCR, Quantitative, Monitoring Chronic Myelogenous Leukemia (CML) | 81206 | 28 | $ - 0 | ||
| 30 | BCR/ABL1 Qualitative Diagnostic Assay with Reflex | 4 | $ - 0 | |||
| 31 | Biliary Tract Malignancy, FISH | 88377 | 2 | $ - 0 | ||
| 32 | Probe, Each Additional (BLPMF) (Bill Only) | 88271x2, 88275 | 6 | $ - 0 | ||
| 33 | B-Cell Lymphoma, Specified FISH, Varies | 88271x2, 88275x 88291 | 2 | $ - 0 | ||
| 34 | B-Cell Lymphoma, FISH, Tissue | 88377 | 2 | $ - 0 | ||
| 35 | Bone Marrow Aspirate | 85097 | 30 | $ - 0 | ||
| 36 | Bone Marrow Biopsy (Bill Only) | 88305 | 20 | $ - 0 | ||
| 37 | Bone Marrow Clot (Bill Only) | 88305 | 26 | $ - 0 | ||
| 38 | BRAF V600E/V600K Somatic Mutation Analysis, Tumor | 81210 | 2 | $ - 0 | ||
| 39 | Broad Range Bacterial PCR and Sequencing | 87801 | 8 | $ - 0 | ||
| 40 | CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN), Reflex | 81219 | 12 | $ - 0 | ||
| 41 | Comprehensive Cardiomyopathy Multi-Gene Panel, Blood | 81439 | 2 | $ - 0 | ||
| 42 | Clostridium difficile Culture | 87081 | 2 | $ - 0 | ||
| 43 | Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid | 82378 | 10 | $ - 0 | ||
| 44 | Chromogranin A, Serum | 86316 | 130 | $ - 0 | ||
| 45 | Chromosome Analysis, Hematologic Disorders, Bone Marrow | 88237, 88291 | 40 | $ - 0 | ||
| 46 | Chromosome Analysis, Congenital Disorders, Blood | 88230, 88291 | 2 | $ - 0 | ||
| 47 | Cutaneous Direct IFA, Biopsy | 88346, 8835x5 | 2 | $ - 0 | ||
| 48 | Coccidioides, Rapid PCR | 87798 | 2 | $ - 0 | ||
| 49 | Chronic Lymphocytic Leukemia (CLL), Diagnostic FISH, Varies | 88271x12, 88275x6, 88291 | 2 | $ - 0 | ||
| 50 | Chromosomal Microarray, Hematologic Disorders | 81277 | 4 | $ - 0 | ||
| 51 | Consult, Outside Slide (Bill Only) | 88321 | 80 | $ - 0 | ||
| 52 | Consult, w/Comp Rvw of His (Bill Only) | 88325 | 62 | $ - 0 | ||
| 53 | Plasma Cell Proliferative Disorder, Pre-Analysis Cell Sorting, Bone Marrow | 88184, 88185x5 | 2 | $ - 0 | ||
| 54 | Consult, w/Slide Prep (Bill Only) | 88323 | 50 | $ - 0 | ||
| 55 | Consult, w/USS Prof (Bill Only) | 88323 | 4 | $ - 0 | ||
| 56 | Decalcification (Bill Only) | 88311 | 28 | $ - 0 | ||
| 57 | EM, Renal Biopsy (Bill Only) | 88348 | 24 | $ - 0 | ||
| 58 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid | 86255x19, 86341 | 2 | $ - 0 | ||
| 59 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum | 86255x19, 86341 | 2 | $ - 0 | ||
| 60 | Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual | 88360x2 | 4 | $ - 0 | ||
| 61 | Hematologic Disorders, DNA Extract and Hold | N/A | 8 | $ - 0 | ||
| 62 | Hematologic Disorders, DNA and RNA Extract and Hold | N/A | 6 | $ - 0 | ||
| 63 | Flow Cytometry Interp, 9-15 Markers | 88188 | 52 | $ - 0 | ||
| 64 | Flow Cytometry Interp, 16 or greater | 88189 | 50 | $ - 0 | ||
| 65 | Flow Cytometry Interp, 2-8 Markers | 88187 | 8 | $ - 0 | ||
| 66 | Flow Cytometry, Cell Surface, First | 88184 | 110 | $ - 0 | ||
| 67 | FLT3 Mutation Analysis, Varies | 81245, 81246 | 4 | $ - 0 | ||
| 68 | Growth Differentiation Factor 15 (GDF15), Plasma | 83520 | 2 | $ - 0 | ||
| 69 | Gadolinium, Urine | 83018 | 2 | $ - 0 | ||
| 70 | Gastrointestinal Dysmotility, Autoimmune/Paraneoplastic Evaluation, Serum | 83519, 86255x6 | 2 | $ - 0 | ||
| 71 | Gastrointestinal Pathogen Panel, PCR, Feces | 87507 | 2 | $ - 0 | ||
| 72 | SpecStain, Frozen (Bill Only) | 88314 | 16 | $ - 0 | ||
| 73 | Helicobacter pylori Culture with Antimicrobial Susceptibilities | 87081 | 2 | $ - 0 | ||
| 74 | 3-Hydroxy-3-Methylglutaryl Coenzyme-A (HMG-CoA) Reductase, Serum | 82397 | 2 | $ - 0 | ||
| 75 | Helicobacter pylori with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Feces | 87798x2 | 4 | $ - 0 | ||
| 76 | Human Papillomavirus (HPV) High/Low Risk, DNA In Situ Hybridization | 88364, 88365 | 4 | $ - 0 | ||
| 77 | IF Additional Stain (Bill Only) | 88350 | 220 | $ - 0 | ||
| 78 | IF Initial Stain (Bill Only) | 88346 | 36 | $ - 0 | ||
| 79 | IHC Multiplex (Bill Only) | 88344 | 2 | $ - 0 | ||
| 80 | IHC Additional Stain (Bill Only) | 88341 | 200 | $ - 0 | ||
| 81 | IHC Initial Stain (Bill Only) | 88342 | 88 | $ - 0 | ||
| 82 | IHC Additional Stain, Tech Only (Bill Only) | 88341 | 66 | $ - 0 | ||
| 83 | IHC Initial Stain, Tech Only (Bill Only) | 88342 | 102 | $ - 0 | ||
| 84 | Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum | 80230 | 60 | $ - 0 | ||
| 85 | Infliximab Antibodies, Serum | 82397 | 36 | $ - 0 | ||
| 86 | Bacterial Identification by Sequencing (Bill Only) | 87798 | 2 | $ - 0 | ||
| 87 | Identification, Next-Generation Sequencing (Bill Only) | 87798 | 6 | $ - 0 | ||
| 88 | ISH Additional Stain (Bill Only) | 88364 | 6 | $ - 0 | ||
| 89 | ISH Initial Stain (Bill Only) | 88365 | 12 | $ - 0 | ||
| 90 | ISH Additional Stain, Tech Only (Bill Only) | 88364 | 2 | $ - 0 | ||
| 91 | ISH Initial Stain, Tech Only (Bill Only) | 88365 | 18 | $ - 0 | ||
| 92 | JAK2 V617F Mutation Detection, Blood | 81270 | 22 | $ - 0 | ||
| 93 | JAK2 Exon 12 and Other Non-V617F Mutation Detection, Blood | 0027U | 2 | $ - 0 | ||
| 94 | Kelch-Like Protein 11 Antibody, Cell Binding Assay, Serum | 86255 | 2 | $ - 0 | ||
| 95 | Level 4 Gross and Microscopic, RB (Bill Only) | 88305 | 20 | $ - 0 | ||
| 96 | M-Protein Isotype by MALDI-TOF Mass Spectrometry, Serum | 0077U | 2 | $ - 0 | ||
| 97 | MayoComplete Melanoma Panel, Next-Generation Sequencing, Tumor | 81445 | 10 | $ - 0 | ||
| 98 | MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor | 81455 | 2 | $ - 0 | ||
| 99 | Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum | 84182, 86255x19, 86341, 86596 | 2 | $ - 0 | ||
| 100 | Susceptibility, Aerobic, MIC | 87186 | 2 | $ - 0 | ||
| 101 | Microdissection, Laser Capture (Bill Only) | 88380 | 6 | $ - 0 | ||
| 102 | Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Ser | 86363 | 2 | $ - 0 | ||
| 103 | MPL Exon 10 Mutation Detection, Reflex | 81339 | 12 | $ - 0 | ||
| 104 | Myeloproliferative Neoplasm (MPN), CALR with Reflex to MPL | 81219 | 2 | $ - 0 | ||
| 105 | MPL Exon 10 Sequencing, Reflex | 81339 | 20 | $ - 0 | ||
| 106 | Mass Spectrometry (Bill Only) | 82542 | 6 | $ - 0 | ||
| 107 | Mycobacterium tuberculosis Complex, Molecular Detection, PCR, Varies | 87556 | 2 | $ - 0 | ||
| 108 | Mycobacterium tuberculosis Complex, Molecular Detection, PCR, FFPE | 87556 | 2 | $ - 0 | ||
| 109 | MYD88 L265P Gene Mutation Analysis | 81305 | 10 | $ - 0 | ||
| 110 | MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next- | 81120, 81121, 81245, 81246, 81352 | 2 | $ - 0 | ||
| 111 | MayoComplete Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing, Varies | 81450 | 10 | $ - 0 | ||
| 112 | Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum | 86053 | 12 | $ - 0 | ||
| 113 | Nuclear Magnetic Resonance (NMR) Lipoprotein Profile, Serum | 83704 | 2 | $ - 0 | ||
| 114 | Orexin-A/Hypocretin-1, Spinal Fluid | 83519 | 2 | $ - 0 | ||
| 115 | Paraneoplastic Autoantibody Evaluation, Serum | 83519, 86255x9, 86596 | 4 | $ - 0 | ||
| 116 | Peripheral Blood (Bill Only) | 85060 | 20 | $ - 0 | ||
| 117 | Peripheral Blood, TC (Bill Only) | 85007 | 30 | $ - 0 | ||
| 118 | Probe, Each Additional (PCPDS) Bill Only | 88271x2, 88274 | 8 | $ - 0 | ||
| 119 | Plasma Cell Proliferative Disorder, High Risk with Reflex Probes, Diagnostic FISH Evaluation, Bone M | 88271x2, 88274, 88291 | 2 | $ - 0 | ||
| 120 | Phospholipase A2 Receptor, Immunofluorescence, Serum | 86255 | 2 | $ - 0 | ||
| 121 | Plasma Cell Proliferative Disorder, FISH, Tissue | Plasma Cell Proliferative Disorder, FISH, Tissue | 2 | $ - 0 | ||
| 122 | Primary Membranous Nephropathy Diagnostic Cascade, Serum | 83520 | 2 | $ - 0 | ||
| 123 | Sarcoma Targeted Gene Fusion/Rearrangement Panels, Next-Generation Sequencing, Tumor | 81479 | 2 | $ - 0 | ||
| 124 | Sickle Solubility, Blood | 85660 | 2 | $ - 0 | ||
| 125 | Slide Review in Molecular Genetics (Bill Only) | 88381 | 19 | $ - 0 | ||
| 126 | Small Lymphocytic Lymphoma, FISH, Tissue | 88377 | 4 | $ - 0 | ||
| 127 | Soluble Fibrin Monomer, Plasma | 85366 | 2 | $ - 0 | ||
| 128 | Programmed Death-Ligand 1 (PD-L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual | 88360 | 6 | $ - 0 | ||
| 129 | SpecStain, Grp I, Microorganisms (Bill Only) | 88312 | 24 | $ - 0 | ||
| 130 | SpecStain, Grp II, Other (Bill Only) | 88313 | 60 | $ - 0 | ||
| 131 | SpecStain, Grp III, Enzyme (Bill Only) | 88319 | 42 | $ - 0 | ||
| 132 | T-Cell Receptor Gene Rearrangement, Bone Marrow | 81340, 81342 | 2 | $ - 0 | ||
| 133 | T-Cell Receptor Gene Rearrangement, Varies | 81340, 81342 | 10 | $ - 0 | ||
| 134 | Thalassemia and Hemoglobinopathy Evaluation, Blood and Serum | 82728, 83020x2, 83021 | 4 | $ - 0 | ||
| 135 | Thrombospondin Type-1 Domain-Containing 7A Antibodies, Serum | 86255 | 2 | $ - 0 | ||
| 136 | Tissue Processing (Bill Only) | 87176 | 2 | $ - 0 | ||
| 137 | Microsatellite Instability, Tumor | 81301 | 2 | $ - 0 | ||
| 138 | Ustekinumab Quantitation with Antibodies, Serum | 80299, 83520 | 28 | $ - 0 | ||
| 139 | Vedolizumab Quantitation with Reflex to Antibodies, Serum | 80280 | 20 | $ - 0 | ||
| 140 | Beta-Globin Cluster Locus Deletion/Duplication, Blood | 81363 | 2 | $ - 0 | ||
| 141 | Beta-Globin Gene Sequencing, Blood | 81364 | 2 | $ - 0 | ||
| 142 | Neuron-Specific Enolase, CSF | 83520 | 18 | $ - 0 | ||
| 143 | Adrenocorticotropic Hormone, Plasma | 82024 | 100 | $ - 0 | ||
| 144 | Ro52 and Ro60 Antibodies, IgG, Serum | 86235x2 | 12 | $ - 0 | ||
| 145 | JAK2 V617F Mutation Detection, Bone Marrow | 81270 | 22 | $ - 0 | ||
| 146 | Vedolizumab Antibodies, Serum | VEMAB | 8 | $ - 0 | ||
| 147 | Myeloproliferative Neoplasm (MPN), JAK2 V617F with reflex to CALR and MPL | 81270 | 20 | $ - 0 | ||
| 148 | KIT Mutation, Exons 8-11 & 17, Hematologic Neoplasms | 81272 | 2 | $ - 0 | ||
| 149 | Total | $ - 0 |
2. Option 1
| CLIN | Service | CPT Code | Estimated Annual Quantity | Base Year Unit Price | Extended Price | Name of Lab Performing Test | Location (City, State) of Lab Performing Test | CLIA Certification Number of Lab Performing Test |
| 1 | Interphases, >=100 (Bill Only) | 88275 | 30 | $ - 0 | ||||
| 2 | Metaphases, 15-20 (Bill Only) | 88262 | 2 | $ - 0 | ||||
| 3 | Metaphases, 20-25 (Bill Only) | 88264 | 36 | $ - 0 | ||||
| 4 | Metaphases, 1-19 (Bill Only) | 88264 | 2 | $ - 0 | ||||
| 5 | Probe, +1 (Bill Only) | 88271 | 2 | $ - 0 | ||||
| 6 | Probe, +2 (Bill Only) | 88271x2 | 26 | $ - 0 | ||||
| 7 | Probe, Each Additional (BLYM) (Bill Only) | 88377 | 2 | $ - 0 | ||||
| 8 | Probe, Each Additional (SLL) (Bill Only) | 88377 | 20 | $ - 0 | ||||
| 9 | Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual | 88360 | 34 | $ - 0 | ||||
| 10 | 25-Hydroxyvitamin D:24,25-Dihydroxyvitamin D Ratio, Serum | 82306, 82542 | 2 | $ - 0 | ||||
| 11 | 3-Methoxytyramine, 24 Hour, Urine | 82542 | 2 | $ - 0 | ||||
| 12 | Thrombophilia Profile, Plasma and Whole Blood | 81240, |
85300, 85303, 85306, 85307, 85379, 85384, 85390, 85610, 85613,
| 85670, 85730 | 2 | $ - 0 | ||||
| 13 | Adalimumab Quantitative with Reflex to Antibody, Serum | 80145 | 74 | $ - 0 | ||
| 14 | Flow Cytometry, Cell Surface, Additional | 88185 | 700 | $ - 0 | ||
| 15 | Adrenocorticotropic Hormone (ACTH), Plasma | 82024 | 370 | $ - 0 | ||
| 16 | Acute Myeloid Leukemia (AML), Specified FISH, Varies | 88271x2, 88275x 88291 | 2 | $ - 0 | ||
| 17 | Adalimumab Antibody, Serum | 83520 | 32 | $ - 0 | ||
| 18 | Amylase, Pancreatic Cyst | 82150 | 10 | $ - 0 | ||
| 19 | Amyloid Protein Identification, Paraffin, LC-MS/MS | 88313 | 6 | $ - 0 | ||
| 20 | APOL1 Genotype, Varies | 81479 | 6 | $ - 0 | ||
| 21 | Alpha-Globin Gene Analysis | 81269 | 2 | $ - 0 | ||
| 22 | Antithrombin Antigen, Plasma | 85301 | 2 | $ - 0 | ||
| 23 | BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR, Quantitative, Monitoring Assay, Varies | 81207 | 2 | $ - 0 | ||
| 24 | BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay | 81206 81208 | 6 | $ - 0 | ||
| 25 | BCR/ABL, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing | 81170 | 2 | $ - 0 | ||
| 26 | B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), Specified FISH, Varies | 88271x2, 88275, 88291 | 2 | $ - 0 | ||
| 27 | Immunoglobulin Gene Rearrangement, Varies | 81261, 81264 | 22 | $ - 0 | ||
| 28 | IGH for B-Cell Chronic Lymphocytic Leukemia (B-CLL), Somatic Hypermutation Analysis | 81263 | 2 | $ - 0 | ||
| 29 | BCR/ABL1, p210, mRNA Detection, RT-PCR, Quantitative, Monitoring Chronic Myelogenous Leukemia (CML) | 81206 | 28 | $ - 0 | ||
| 30 | BCR/ABL1 Qualitative Diagnostic Assay with Reflex | 4 | $ - 0 | |||
| 31 | Biliary Tract Malignancy, FISH | 88377 | 2 | $ - 0 | ||
| 32 | Probe, Each Additional (BLPMF) (Bill Only) | 88271x2, 88275 | 6 | $ - 0 | ||
| 33 | B-Cell Lymphoma, Specified FISH, Varies | 88271x2, 88275x 88291 | 2 | $ - 0 | ||
| 34 | B-Cell Lymphoma, FISH, Tissue | 88377 | 2 | $ - 0 | ||
| 35 | Bone Marrow Aspirate | 85097 | 30 | $ - 0 | ||
| 36 | Bone Marrow Biopsy (Bill Only) | 88305 | 20 | $ - 0 | ||
| 37 | Bone Marrow Clot (Bill Only) | 88305 | 26 | $ - 0 | ||
| 38 | BRAF V600E/V600K Somatic Mutation Analysis, Tumor | 81210 | 2 | $ - 0 | ||
| 39 | Broad Range Bacterial PCR and Sequencing | 87801 | 8 | $ - 0 | ||
| 40 | CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN), Reflex | 81219 | 12 | $ - 0 | ||
| 41 | Comprehensive Cardiomyopathy Multi-Gene Panel, Blood | 81439 | 2 | $ - 0 | ||
| 42 | Clostridium difficile Culture | 87081 | 2 | $ - 0 | ||
| 43 | Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid | 82378 | 10 | $ - 0 | ||
| 44 | Chromogranin A, Serum | 86316 | 130 | $ - 0 | ||
| 45 | Chromosome Analysis, Hematologic Disorders, Bone Marrow | 88237, 88291 | 40 | $ - 0 | ||
| 46 | Chromosome Analysis, Congenital Disorders, Blood | 88230, 88291 | 2 | $ - 0 | ||
| 47 | Cutaneous Direct IFA, Biopsy | 88346, 8835x5 | 2 | $ - 0 | ||
| 48 | Coccidioides, Rapid PCR | 87798 | 2 | $ - 0 | ||
| 49 | Chronic Lymphocytic Leukemia (CLL), Diagnostic FISH, Varies | 88271x12, 88275x6, 88291 | 2 | $ - 0 | ||
| 50 | Chromosomal Microarray, Hematologic Disorders | 81277 | 4 | $ - 0 | ||
| 51 | Consult, Outside Slide (Bill Only) | 88321 | 80 | $ - 0 | ||
| 52 | Consult, w/Comp Rvw of His (Bill Only) | 88325 | 62 | $ - 0 | ||
| 53 | Plasma Cell Proliferative Disorder, Pre-Analysis Cell Sorting, Bone Marrow | 88184, 88185x5 | 2 | $ - 0 | ||
| 54 | Consult, w/Slide Prep (Bill Only) | 88323 | 50 | $ - 0 | ||
| 55 | Consult, w/USS Prof (Bill Only) | 88323 | 4 | $ - 0 | ||
| 56 | Decalcification (Bill Only) | 88311 | 28 | $ - 0 | ||
| 57 | EM, Renal Biopsy (Bill Only) | 88348 | 24 | $ - 0 | ||
| 58 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid | 86255x19, 86341 | 2 | $ - 0 | ||
| 59 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum | 86255x19, 86341 | 2 | $ - 0 | ||
| 60 | Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual | 88360x2 | 4 | $ - 0 | ||
| 61 | Hematologic Disorders, DNA Extract and Hold | N/A | 8 | $ - 0 | ||
| 62 | Hematologic Disorders, DNA and RNA Extract and Hold | N/A | 6 | $ - 0 | ||
| 63 | Flow Cytometry Interp, 9-15 Markers | 88188 | 52 | $ - 0 | ||
| 64 | Flow Cytometry Interp, 16 or greater | 88189 | 50 | $ - 0 | ||
| 65 | Flow Cytometry Interp, 2-8 Markers | 88187 | 8 | $ - 0 | ||
| 66 | Flow Cytometry, Cell Surface, First | 88184 | 110 | $ - 0 | ||
| 67 | FLT3 Mutation Analysis, Varies | 81245, 81246 | 4 | $ - 0 | ||
| 68 | Growth Differentiation Factor 15 (GDF15), Plasma | 83520 | 2 | $ - 0 | ||
| 69 | Gadolinium, Urine | 83018 | 2 | $ - 0 | ||
| 70 | Gastrointestinal Dysmotility, Autoimmune/Paraneoplastic Evaluation, Serum | 83519, 86255x6 | 2 | $ - 0 | ||
| 71 | Gastrointestinal Pathogen Panel, PCR, Feces | 87507 | 2 | $ - 0 | ||
| 72 | SpecStain, Frozen (Bill Only) | 88314 | 16 | $ - 0 | ||
| 73 | Helicobacter pylori Culture with Antimicrobial Susceptibilities | 87081 | 2 | $ - 0 | ||
| 74 | 3-Hydroxy-3-Methylglutaryl Coenzyme-A (HMG-CoA) Reductase, Serum | 82397 | 2 | $ - 0 | ||
| 75 | Helicobacter pylori with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Feces | 87798x2 | 4 | $ - 0 | ||
| 76 | Human Papillomavirus (HPV) High/Low Risk, DNA In Situ Hybridization | 88364, 88365 | 4 | $ - 0 | ||
| 77 | IF Additional Stain (Bill Only) | 88350 | 220 | $ - 0 | ||
| 78 | IF Initial Stain (Bill Only) | 88346 | 36 | $ - 0 | ||
| 79 | IHC Multiplex (Bill Only) | 88344 | 2 | $ - 0 | ||
| 80 | IHC Additional Stain (Bill Only) | 88341 | 200 | $ - 0 | ||
| 81 | IHC Initial Stain (Bill Only) | 88342 | 88 | $ - 0 | ||
| 82 | IHC Additional Stain, Tech Only (Bill Only) | 88341 | 66 | $ - 0 | ||
| 83 | IHC Initial Stain, Tech Only (Bill Only) | 88342 | 102 | $ - 0 | ||
| 84 | Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum | 80230 | 60 | $ - 0 | ||
| 85 | Infliximab Antibodies, Serum | 82397 | 36 | $ - 0 | ||
| 86 | Bacterial Identification by Sequencing (Bill Only) | 87798 | 2 | $ - 0 | ||
| 87 | Identification, Next-Generation Sequencing (Bill Only) | 87798 | 6 | $ - 0 | ||
| 88 | ISH Additional Stain (Bill Only) | 88364 | 6 | $ - 0 | ||
| 89 | ISH Initial Stain (Bill Only) | 88365 | 12 | $ - 0 | ||
| 90 | ISH Additional Stain, Tech Only (Bill Only) | 88364 | 2 | $ - 0 | ||
| 91 | ISH Initial Stain, Tech Only (Bill Only) | 88365 | 18 | $ - 0 | ||
| 92 | JAK2 V617F Mutation Detection, Blood | 81270 | 22 | $ - 0 | ||
| 93 | JAK2 Exon 12 and Other Non-V617F Mutation Detection, Blood | 0027U | 2 | $ - 0 | ||
| 94 | Kelch-Like Protein 11 Antibody, Cell Binding Assay, Serum | 86255 | 2 | $ - 0 | ||
| 95 | Level 4 Gross and Microscopic, RB (Bill Only) | 88305 | 20 | $ - 0 | ||
| 96 | M-Protein Isotype by MALDI-TOF Mass Spectrometry, Serum | 0077U | 2 | $ - 0 | ||
| 97 | MayoComplete Melanoma Panel, Next-Generation Sequencing, Tumor | 81445 | 10 | $ - 0 | ||
| 98 | MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor | 81455 | 2 | $ - 0 | ||
| 99 | Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum | 84182, 86255x19, 86341, 86596 | 2 | $ - 0 | ||
| 100 | Susceptibility, Aerobic, MIC | 87186 | 2 | $ - 0 | ||
| 101 | Microdissection, Laser Capture (Bill Only) | 88380 | 6 | $ - 0 | ||
| 102 | Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Ser | 86363 | 2 | $ - 0 | ||
| 103 | MPL Exon 10 Mutation Detection, Reflex | 81339 | 12 | $ - 0 | ||
| 104 | Myeloproliferative Neoplasm (MPN), CALR with Reflex to MPL | 81219 | 2 | $ - 0 | ||
| 105 | MPL Exon 10 Sequencing, Reflex | 81339 | 20 | $ - 0 | ||
| 106 | Mass Spectrometry (Bill Only) | 82542 | 6 | $ - 0 | ||
| 107 | Mycobacterium tuberculosis Complex, Molecular Detection, PCR, Varies | 87556 | 2 | $ - 0 | ||
| 108 | Mycobacterium tuberculosis Complex, Molecular Detection, PCR, FFPE | 87556 | 2 | $ - 0 | ||
| 109 | MYD88 L265P Gene Mutation Analysis | 81305 | 10 | $ - 0 | ||
| 110 | MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next- | 81120, 81121, 81245, 81246, 81352 | 2 | $ - 0 | ||
| 111 | MayoComplete Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing, Varies | 81450 | 10 | $ - 0 | ||
| 112 | Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum | 86053 | 12 | $ - 0 | ||
| 113 | Nuclear Magnetic Resonance (NMR) Lipoprotein Profile, Serum | 83704 | 2 | $ - 0 | ||
| 114 | Orexin-A/Hypocretin-1, Spinal Fluid | 83519 | 2 | $ - 0 | ||
| 115 | Paraneoplastic Autoantibody Evaluation, Serum | 83519, 86255x9, 86596 | 4 | $ - 0 | ||
| 116 | Peripheral Blood (Bill Only) | 85060 | 20 | $ - 0 | ||
| 117 | Peripheral Blood, TC (Bill Only) | 85007 | 30 | $ - 0 | ||
| 118 | Probe, Each Additional (PCPDS) Bill Only | 88271x2, 88274 | 8 | $ - 0 | ||
| 119 | Plasma Cell Proliferative Disorder, High Risk with Reflex Probes, Diagnostic FISH Evaluation, Bone M | 88271x2, 88274, 88291 | 2 | $ - 0 | ||
| 120 | Phospholipase A2 Receptor, Immunofluorescence, Serum | 86255 | 2 | $ - 0 | ||
| 121 | Plasma Cell Proliferative Disorder, FISH, Tissue | Plasma Cell Proliferative Disorder, FISH, Tissue | 2 | $ - 0 | ||
| 122 | Primary Membranous Nephropathy Diagnostic Cascade, Serum | 83520 | 2 | $ - 0 | ||
| 123 | Sarcoma Targeted Gene Fusion/Rearrangement Panels, Next-Generation Sequencing, Tumor | 81479 | 2 | $ - 0 | ||
| 124 | Sickle Solubility, Blood | 85660 | 2 | $ - 0 | ||
| 125 | Slide Review in Molecular Genetics (Bill Only) | 88381 | 19 | $ - 0 | ||
| 126 | Small Lymphocytic Lymphoma, FISH, Tissue | 88377 | 4 | $ - 0 | ||
| 127 | Soluble Fibrin Monomer, Plasma | 85366 | 2 | $ - 0 | ||
| 128 | Programmed Death-Ligand 1 (PD-L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual | 88360 | 6 | $ - 0 | ||
| 129 | SpecStain, Grp I, Microorganisms (Bill Only) | 88312 | 24 | $ - 0 | ||
| 130 | SpecStain, Grp II, Other (Bill Only) | 88313 | 60 | $ - 0 | ||
| 131 | SpecStain, Grp III, Enzyme (Bill Only) | 88319 | 42 | $ - 0 | ||
| 132 | T-Cell Receptor Gene Rearrangement, Bone Marrow | 81340, 81342 | 2 | $ - 0 | ||
| 133 | T-Cell Receptor Gene Rearrangement, Varies | 81340, 81342 | 10 | $ - 0 | ||
| 134 | Thalassemia and Hemoglobinopathy Evaluation, Blood and Serum | 82728, 83020x2, 83021 | 4 | $ - 0 | ||
| 135 | Thrombospondin Type-1 Domain-Containing 7A Antibodies, Serum | 86255 | 2 | $ - 0 | ||
| 136 | Tissue Processing (Bill Only) | 87176 | 2 | $ - 0 | ||
| 137 | Microsatellite Instability, Tumor | 81301 | 2 | $ - 0 | ||
| 138 | Ustekinumab Quantitation with Antibodies, Serum | 80299, 83520 | 28 | $ - 0 | ||
| 139 | Vedolizumab Quantitation with Reflex to Antibodies, Serum | 80280 | 20 | $ - 0 | ||
| 140 | Beta-Globin Cluster Locus Deletion/Duplication, Blood | 81363 | 2 | $ - 0 | ||
| 141 | Beta-Globin Gene Sequencing, Blood | 81364 | 2 | $ - 0 | ||
| 142 | Neuron-Specific Enolase, CSF | 83520 | 18 | $ - 0 | ||
| 143 | Adrenocorticotropic Hormone, Plasma | 82024 | 100 | $ - 0 | ||
| 144 | Ro52 and Ro60 Antibodies, IgG, Serum | 86235x2 | 12 | $ - 0 | ||
| 145 | JAK2 V617F Mutation Detection, Bone Marrow | 81270 | 22 | $ - 0 | ||
| 146 | Vedolizumab Antibodies, Serum | VEMAB | 8 | $ - 0 | ||
| 147 | Myeloproliferative Neoplasm (MPN), JAK2 V617F with reflex to CALR and MPL | 81270 | 20 | $ - 0 | ||
| 148 | KIT Mutation, Exons 8-11 & 17, Hematologic Neoplasms | 81272 | 2 | $ - 0 | ||
| 149 | Total | $ - 0 |
3. Option 2
| CLIN | Service | CPT Code | Estimated Annual Quantity | Base Year Unit Price | Extended Price | Name of Lab Performing Test | Location (City, State) of Lab Performing Test | CLIA Certification Number of Lab Performing Test |
| 1 | Interphases, >=100 (Bill Only) | 88275 | 30 | $ - 0 | ||||
| 2 | Metaphases, 15-20 (Bill Only) | 88262 | 2 | $ - 0 | ||||
| 3 | Metaphases, 20-25 (Bill Only) | 88264 | 36 | $ - 0 | ||||
| 4 | Metaphases, 1-19 (Bill Only) | 88264 | 2 | $ - 0 | ||||
| 5 | Probe, +1 (Bill Only) | 88271 | 2 | $ - 0 | ||||
| 6 | Probe, +2 (Bill Only) | 88271x2 | 26 | $ - 0 | ||||
| 7 | Probe, Each Additional (BLYM) (Bill Only) | 88377 | 2 | $ - 0 | ||||
| 8 | Probe, Each Additional (SLL) (Bill Only) | 88377 | 20 | $ - 0 | ||||
| 9 | Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual | 88360 | 34 | $ - 0 | ||||
| 10 | 25-Hydroxyvitamin D:24,25-Dihydroxyvitamin D Ratio, Serum | 82306, 82542 | 2 | $ - 0 | ||||
| 11 | 3-Methoxytyramine, 24 Hour, Urine | 82542 | 2 | $ - 0 | ||||
| 12 | Thrombophilia Profile, Plasma and Whole Blood | 81240, |
85300, 85303, 85306, 85307, 85379, 85384, 85390, 85610, 85613,
| 85670, 85730 | 2 | $ - 0 | ||||
| 13 | Adalimumab Quantitative with Reflex to Antibody, Serum | 80145 | 74 | $ - 0 | ||
| 14 | Flow Cytometry, Cell Surface, Additional | 88185 | 700 | $ - 0 | ||
| 15 | Adrenocorticotropic Hormone (ACTH), Plasma | 82024 | 370 | $ - 0 | ||
| 16 | Acute Myeloid Leukemia (AML), Specified FISH, Varies | 88271x2, 88275x 88291 | 2 | $ - 0 | ||
| 17 | Adalimumab Antibody, Serum | 83520 | 32 | $ - 0 | ||
| 18 | Amylase, Pancreatic Cyst | 82150 | 10 | $ - 0 | ||
| 19 | Amyloid Protein Identification, Paraffin, LC-MS/MS | 88313 | 6 | $ - 0 | ||
| 20 | APOL1 Genotype, Varies | 81479 | 6 | $ - 0 | ||
| 21 | Alpha-Globin Gene Analysis | 81269 | 2 | $ - 0 | ||
| 22 | Antithrombin Antigen, Plasma | 85301 | 2 | $ - 0 | ||
| 23 | BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR, Quantitative, Monitoring Assay, Varies | 81207 | 2 | $ - 0 | ||
| 24 | BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay | 81206 81208 | 6 | $ - 0 | ||
| 25 | BCR/ABL, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing | 81170 | 2 | $ - 0 | ||
| 26 | B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), Specified FISH, Varies | 88271x2, 88275, 88291 | 2 | $ - 0 | ||
| 27 | Immunoglobulin Gene Rearrangement, Varies | 81261, 81264 | 22 | $ - 0 | ||
| 28 | IGH for B-Cell Chronic Lymphocytic Leukemia (B-CLL), Somatic Hypermutation Analysis | 81263 | 2 | $ - 0 | ||
| 29 | BCR/ABL1, p210, mRNA Detection, RT-PCR, Quantitative, Monitoring Chronic Myelogenous Leukemia (CML) | 81206 | 28 | $ - 0 | ||
| 30 | BCR/ABL1 Qualitative Diagnostic Assay with Reflex | 4 | $ - 0 | |||
| 31 | Biliary Tract Malignancy, FISH | 88377 | 2 | $ - 0 | ||
| 32 | Probe, Each Additional (BLPMF) (Bill Only) | 88271x2, 88275 | 6 | $ - 0 | ||
| 33 | B-Cell Lymphoma, Specified FISH, Varies | 88271x2, 88275x 88291 | 2 | $ - 0 | ||
| 34 | B-Cell Lymphoma, FISH, Tissue | 88377 | 2 | $ - 0 | ||
| 35 | Bone Marrow Aspirate | 85097 | 30 | $ - 0 | ||
| 36 | Bone Marrow Biopsy (Bill Only) | 88305 | 20 | $ - 0 | ||
| 37 | Bone Marrow Clot (Bill Only) | 88305 | 26 | $ - 0 | ||
| 38 | BRAF V600E/V600K Somatic Mutation Analysis, Tumor | 81210 | 2 | $ - 0 | ||
| 39 | Broad Range Bacterial PCR and Sequencing | 87801 | 8 | $ - 0 | ||
| 40 | CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN), Reflex | 81219 | 12 | $ - 0 | ||
| 41 | Comprehensive Cardiomyopathy Multi-Gene Panel, Blood | 81439 | 2 | $ - 0 | ||
| 42 | Clostridium difficile Culture | 87081 | 2 | $ - 0 | ||
| 43 | Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid | 82378 | 10 | $ - 0 | ||
| 44 | Chromogranin A, Serum | 86316 | 130 | $ - 0 | ||
| 45 | Chromosome Analysis, Hematologic Disorders, Bone Marrow | 88237, 88291 | 40 | $ - 0 | ||
| 46 | Chromosome Analysis, Congenital Disorders, Blood | 88230, 88291 | 2 | $ - 0 | ||
| 47 | Cutaneous Direct IFA, Biopsy | 88346, 8835x5 | 2 | $ - 0 | ||
| 48 | Coccidioides, Rapid PCR | 87798 | 2 | $ - 0 | ||
| 49 | Chronic Lymphocytic Leukemia (CLL), Diagnostic FISH, Varies | 88271x12, 88275x6, 88291 | 2 | $ - 0 | ||
| 50 | Chromosomal Microarray, Hematologic Disorders | 81277 | 4 | $ - 0 | ||
| 51 | Consult, Outside Slide (Bill Only) | 88321 | 80 | $ - 0 | ||
| 52 | Consult, w/Comp Rvw of His (Bill Only) | 88325 | 62 | $ - 0 | ||
| 53 | Plasma Cell Proliferative Disorder, Pre-Analysis Cell Sorting, Bone Marrow | 88184, 88185x5 | 2 | $ - 0 | ||
| 54 | Consult, w/Slide Prep (Bill Only) | 88323 | 50 | $ - 0 | ||
| 55 | Consult, w/USS Prof (Bill Only) | 88323 | 4 | $ - 0 | ||
| 56 | Decalcification (Bill Only) | 88311 | 28 | $ - 0 | ||
| 57 | EM, Renal Biopsy (Bill Only) | 88348 | 24 | $ - 0 | ||
| 58 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid | 86255x19, 86341 | 2 | $ - 0 | ||
| 59 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum | 86255x19, 86341 | 2 | $ - 0 | ||
| 60 | Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual | 88360x2 | 4 | $ - 0 | ||
| 61 | Hematologic Disorders, DNA Extract and Hold | N/A | 8 | $ - 0 | ||
| 62 | Hematologic Disorders, DNA and RNA Extract and Hold | N/A | 6 | $ - 0 | ||
| 63 | Flow Cytometry Interp, 9-15 Markers | 88188 | 52 | $ - 0 | ||
| 64 | Flow Cytometry Interp, 16 or greater | 88189 | 50 | $ - 0 | ||
| 65 | Flow Cytometry Interp, 2-8 Markers | 88187 | 8 | $ - 0 | ||
| 66 | Flow Cytometry, Cell Surface, First | 88184 | 110 | $ - 0 | ||
| 67 | FLT3 Mutation Analysis, Varies | 81245, 81246 | 4 | $ - 0 | ||
| 68 | Growth Differentiation Factor 15 (GDF15), Plasma | 83520 | 2 | $ - 0 | ||
| 69 | Gadolinium, Urine | 83018 | 2 | $ - 0 | ||
| 70 | Gastrointestinal Dysmotility, Autoimmune/Paraneoplastic Evaluation, Serum | 83519, 86255x6 | 2 | $ - 0 | ||
| 71 | Gastrointestinal Pathogen Panel, PCR, Feces | 87507 | 2 | $ - 0 | ||
| 72 | SpecStain, Frozen (Bill Only) | 88314 | 16 | $ - 0 | ||
| 73 | Helicobacter pylori Culture with Antimicrobial Susceptibilities | 87081 | 2 | $ - 0 | ||
| 74 | 3-Hydroxy-3-Methylglutaryl Coenzyme-A (HMG-CoA) Reductase, Serum | 82397 | 2 | $ - 0 | ||
| 75 | Helicobacter pylori with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Feces | 87798x2 | 4 | $ - 0 | ||
| 76 | Human Papillomavirus (HPV) High/Low Risk, DNA In Situ Hybridization | 88364, 88365 | 4 | $ - 0 | ||
| 77 | IF Additional Stain (Bill Only) | 88350 | 220 | $ - 0 | ||
| 78 | IF Initial Stain (Bill Only) | 88346 | 36 | $ - 0 | ||
| 79 | IHC Multiplex (Bill Only) | 88344 | 2 | $ - 0 | ||
| 80 | IHC Additional Stain (Bill Only) | 88341 | 200 | $ - 0 | ||
| 81 | IHC Initial Stain (Bill Only) | 88342 | 88 | $ - 0 | ||
| 82 | IHC Additional Stain, Tech Only (Bill Only) | 88341 | 66 | $ - 0 | ||
| 83 | IHC Initial Stain, Tech Only (Bill Only) | 88342 | 102 | $ - 0 | ||
| 84 | Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum | 80230 | 60 | $ - 0 | ||
| 85 | Infliximab Antibodies, Serum | 82397 | 36 | $ - 0 | ||
| 86 | Bacterial Identification by Sequencing (Bill Only) | 87798 | 2 | $ - 0 | ||
| 87 | Identification, Next-Generation Sequencing (Bill Only) | 87798 | 6 | $ - 0 | ||
| 88 | ISH Additional Stain (Bill Only) | 88364 | 6 | $ - 0 | ||
| 89 | ISH Initial Stain (Bill Only) | 88365 | 12 | $ - 0 | ||
| 90 | ISH Additional Stain, Tech Only (Bill Only) | 88364 | 2 | $ - 0 | ||
| 91 | ISH Initial Stain, Tech Only (Bill Only) | 88365 | 18 | $ - 0 | ||
| 92 | JAK2 V617F Mutation Detection, Blood | 81270 | 22 | $ - 0 | ||
| 93 | JAK2 Exon 12 and Other Non-V617F Mutation Detection, Blood | 0027U | 2 | $ - 0 | ||
| 94 | Kelch-Like Protein 11 Antibody, Cell Binding Assay, Serum | 86255 | 2 | $ - 0 | ||
| 95 | Level 4 Gross and Microscopic, RB (Bill Only) | 88305 | 20 | $ - 0 | ||
| 96 | M-Protein Isotype by MALDI-TOF Mass Spectrometry, Serum | 0077U | 2 | $ - 0 | ||
| 97 | MayoComplete Melanoma Panel, Next-Generation Sequencing, Tumor | 81445 | 10 | $ - 0 | ||
| 98 | MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor | 81455 | 2 | $ - 0 | ||
| 99 | Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum | 84182, 86255x19, 86341, 86596 | 2 | $ - 0 | ||
| 100 | Susceptibility, Aerobic, MIC | 87186 | 2 | $ - 0 | ||
| 101 | Microdissection, Laser Capture (Bill Only) | 88380 | 6 | $ - 0 | ||
| 102 | Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Ser | 86363 | 2 | $ - 0 | ||
| 103 | MPL Exon 10 Mutation Detection, Reflex | 81339 | 12 | $ - 0 | ||
| 104 | Myeloproliferative Neoplasm (MPN), CALR with Reflex to MPL | 81219 | 2 | $ - 0 | ||
| 105 | MPL Exon 10 Sequencing, Reflex | 81339 | 20 | $ - 0 | ||
| 106 | Mass Spectrometry (Bill Only) | 82542 | 6 | $ - 0 | ||
| 107 | Mycobacterium tuberculosis Complex, Molecular Detection, PCR, Varies | 87556 | 2 | $ - 0 | ||
| 108 | Mycobacterium tuberculosis Complex, Molecular Detection, PCR, FFPE | 87556 | 2 | $ - 0 | ||
| 109 | MYD88 L265P Gene Mutation Analysis | 81305 | 10 | $ - 0 | ||
| 110 | MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next- | 81120, 81121, 81245, 81246, 81352 | 2 | $ - 0 | ||
| 111 | MayoComplete Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing, Varies | 81450 | 10 | $ - 0 | ||
| 112 | Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum | 86053 | 12 | $ - 0 | ||
| 113 | Nuclear Magnetic Resonance (NMR) Lipoprotein Profile, Serum | 83704 | 2 | $ - 0 | ||
| 114 | Orexin-A/Hypocretin-1, Spinal Fluid | 83519 | 2 | $ - 0 | ||
| 115 | Paraneoplastic Autoantibody Evaluation, Serum | 83519, 86255x9, 86596 | 4 | $ - 0 | ||
| 116 | Peripheral Blood (Bill Only) | 85060 | 20 | $ - 0 | ||
| 117 | Peripheral Blood, TC (Bill Only) | 85007 | 30 | $ - 0 | ||
| 118 | Probe, Each Additional (PCPDS) Bill Only | 88271x2, 88274 | 8 | $ - 0 | ||
| 119 | Plasma Cell Proliferative Disorder, High Risk with Reflex Probes, Diagnostic FISH Evaluation, Bone M | 88271x2, 88274, 88291 | 2 | $ - 0 | ||
| 120 | Phospholipase A2 Receptor, Immunofluorescence, Serum | 86255 | 2 | $ - 0 | ||
| 121 | Plasma Cell Proliferative Disorder, FISH, Tissue | Plasma Cell Proliferative Disorder, FISH, Tissue | 2 | $ - 0 | ||
| 122 | Primary Membranous Nephropathy Diagnostic Cascade, Serum | 83520 | 2 | $ - 0 | ||
| 123 | Sarcoma Targeted Gene Fusion/Rearrangement Panels, Next-Generation Sequencing, Tumor | 81479 | 2 | $ - 0 | ||
| 124 | Sickle Solubility, Blood | 85660 | 2 | $ - 0 | ||
| 125 | Slide Review in Molecular Genetics (Bill Only) | 88381 | 19 | $ - 0 | ||
| 126 | Small Lymphocytic Lymphoma, FISH, Tissue | 88377 | 4 | $ - 0 | ||
| 127 | Soluble Fibrin Monomer, Plasma | 85366 | 2 | $ - 0 | ||
| 128 | Programmed Death-Ligand 1 (PD-L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual | 88360 | 6 | $ - 0 | ||
| 129 | SpecStain, Grp I, Microorganisms (Bill Only) | 88312 | 24 | $ - 0 | ||
| 130 | SpecStain, Grp II, Other (Bill Only) | 88313 | 60 | $ - 0 | ||
| 131 | SpecStain, Grp III, Enzyme (Bill Only) | 88319 | 42 | $ - 0 | ||
| 132 | T-Cell Receptor Gene Rearrangement, Bone Marrow | 81340, 81342 | 2 | $ - 0 | ||
| 133 | T-Cell Receptor Gene Rearrangement, Varies | 81340, 81342 | 10 | $ - 0 | ||
| 134 | Thalassemia and Hemoglobinopathy Evaluation, Blood and Serum | 82728, 83020x2, 83021 | 4 | $ - 0 | ||
| 135 | Thrombospondin Type-1 Domain-Containing 7A Antibodies, Serum | 86255 | 2 | $ - 0 | ||
| 136 | Tissue Processing (Bill Only) | 87176 | 2 | $ - 0 | ||
| 137 | Microsatellite Instability, Tumor | 81301 | 2 | $ - 0 | ||
| 138 | Ustekinumab Quantitation with Antibodies, Serum | 80299, 83520 | 28 | $ - 0 | ||
| 139 | Vedolizumab Quantitation with Reflex to Antibodies, Serum | 80280 | 20 | $ - 0 | ||
| 140 | Beta-Globin Cluster Locus Deletion/Duplication, Blood | 81363 | 2 | $ - 0 | ||
| 141 | Beta-Globin Gene Sequencing, Blood | 81364 | 2 | $ - 0 | ||
| 142 | Neuron-Specific Enolase, CSF | 83520 | 18 | $ - 0 | ||
| 143 | Adrenocorticotropic Hormone, Plasma | 82024 | 100 | $ - 0 | ||
| 144 | Ro52 and Ro60 Antibodies, IgG, Serum | 86235x2 | 12 | $ - 0 | ||
| 145 | JAK2 V617F Mutation Detection, Bone Marrow | 81270 | 22 | $ - 0 | ||
| 146 | Vedolizumab Antibodies, Serum | VEMAB | 8 | $ - 0 | ||
| 147 | Myeloproliferative Neoplasm (MPN), JAK2 V617F with reflex to CALR and MPL | 81270 | 20 | $ - 0 | ||
| 148 | KIT Mutation, Exons 8-11 & 17, Hematologic Neoplasms | 81272 | 2 | $ - 0 | ||
| 149 | Total | $ - 0 |
4. Option 3
| CLIN | Service | CPT Code | Estimated Annual Quantity | Base Year Unit Price | Extended Price | Name of Lab Performing Test | Location (City, State) of Lab Performing Test | CLIA Certification Number of Lab Performing Test |
| 1 | Interphases, >=100 (Bill Only) | 88275 | 30 | $ - 0 | ||||
| 2 | Metaphases, 15-20 (Bill Only) | 88262 | 2 | $ - 0 | ||||
| 3 | Metaphases, 20-25 (Bill Only) | 88264 | 36 | $ - 0 | ||||
| 4 | Metaphases, 1-19 (Bill Only) | 88264 | 2 | $ - 0 | ||||
| 5 | Probe, +1 (Bill Only) | 88271 | 2 | $ - 0 | ||||
| 6 | Probe, +2 (Bill Only) | 88271x2 | 26 | $ - 0 | ||||
| 7 | Probe, Each Additional (BLYM) (Bill Only) | 88377 | 2 | $ - 0 | ||||
| 8 | Probe, Each Additional (SLL) (Bill Only) | 88377 | 20 | $ - 0 | ||||
| 9 | Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual | 88360 | 34 | $ - 0 | ||||
| 10 | 25-Hydroxyvitamin D:24,25-Dihydroxyvitamin D Ratio, Serum | 82306, 82542 | 2 | $ - 0 | ||||
| 11 | 3-Methoxytyramine, 24 Hour, Urine | 82542 | 2 | $ - 0 | ||||
| 12 | Thrombophilia Profile, Plasma and Whole Blood | 81240, |
85300, 85303, 85306, 85307, 85379, 85384, 85390, 85610, 85613,
| 85670, 85730 | 2 | $ - 0 | ||||
| 13 | Adalimumab Quantitative with Reflex to Antibody, Serum | 80145 | 74 | $ - 0 | ||
| 14 | Flow Cytometry, Cell Surface, Additional | 88185 | 700 | $ - 0 | ||
| 15 | Adrenocorticotropic Hormone (ACTH), Plasma | 82024 | 370 | $ - 0 | ||
| 16 | Acute Myeloid Leukemia (AML), Specified FISH, Varies | 88271x2, 88275x 88291 | 2 | $ - 0 | ||
| 17 | Adalimumab Antibody, Serum | 83520 | 32 | $ - 0 | ||
| 18 | Amylase, Pancreatic Cyst | 82150 | 10 | $ - 0 | ||
| 19 | Amyloid Protein Identification, Paraffin, LC-MS/MS | 88313 | 6 | $ - 0 | ||
| 20 | APOL1 Genotype, Varies | 81479 | 6 | $ - 0 | ||
| 21 | Alpha-Globin Gene Analysis | 81269 | 2 | $ - 0 | ||
| 22 | Antithrombin Antigen, Plasma | 85301 | 2 | $ - 0 | ||
| 23 | BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR, Quantitative, Monitoring Assay, Varies | 81207 | 2 | $ - 0 | ||
| 24 | BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay | 81206 81208 | 6 | $ - 0 | ||
| 25 | BCR/ABL, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing | 81170 | 2 | $ - 0 | ||
| 26 | B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), Specified FISH, Varies | 88271x2, 88275, 88291 | 2 | $ - 0 | ||
| 27 | Immunoglobulin Gene Rearrangement, Varies | 81261, 81264 | 22 | $ - 0 | ||
| 28 | IGH for B-Cell Chronic Lymphocytic Leukemia (B-CLL), Somatic Hypermutation Analysis | 81263 | 2 | $ - 0 | ||
| 29 | BCR/ABL1, p210, mRNA Detection, RT-PCR, Quantitative, Monitoring Chronic Myelogenous Leukemia (CML) | 81206 | 28 | $ - 0 | ||
| 30 | BCR/ABL1 Qualitative Diagnostic Assay with Reflex | 4 | $ - 0 | |||
| 31 | Biliary Tract Malignancy, FISH | 88377 | 2 | $ - 0 | ||
| 32 | Probe, Each Additional (BLPMF) (Bill Only) | 88271x2, 88275 | 6 | $ - 0 | ||
| 33 | B-Cell Lymphoma, Specified FISH, Varies | 88271x2, 88275x 88291 | 2 | $ - 0 | ||
| 34 | B-Cell Lymphoma, FISH, Tissue | 88377 | 2 | $ - 0 | ||
| 35 | Bone Marrow Aspirate | 85097 | 30 | $ - 0 | ||
| 36 | Bone Marrow Biopsy (Bill Only) | 88305 | 20 | $ - 0 | ||
| 37 | Bone Marrow Clot (Bill Only) | 88305 | 26 | $ - 0 | ||
| 38 | BRAF V600E/V600K Somatic Mutation Analysis, Tumor | 81210 | 2 | $ - 0 | ||
| 39 | Broad Range Bacterial PCR and Sequencing | 87801 | 8 | $ - 0 | ||
| 40 | CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN), Reflex | 81219 | 12 | $ - 0 | ||
| 41 | Comprehensive Cardiomyopathy Multi-Gene Panel, Blood | 81439 | 2 | $ - 0 | ||
| 42 | Clostridium difficile Culture | 87081 | 2 | $ - 0 | ||
| 43 | Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid | 82378 | 10 | $ - 0 | ||
| 44 | Chromogranin A, Serum | 86316 | 130 | $ - 0 | ||
| 45 | Chromosome Analysis, Hematologic Disorders, Bone Marrow | 88237, 88291 | 40 | $ - 0 | ||
| 46 | Chromosome Analysis, Congenital Disorders, Blood | 88230, 88291 | 2 | $ - 0 | ||
| 47 | Cutaneous Direct IFA, Biopsy | 88346, 8835x5 | 2 | $ - 0 | ||
| 48 | Coccidioides, Rapid PCR | 87798 | 2 | $ - 0 | ||
| 49 | Chronic Lymphocytic Leukemia (CLL), Diagnostic FISH, Varies | 88271x12, 88275x6, 88291 | 2 | $ - 0 | ||
| 50 | Chromosomal Microarray, Hematologic Disorders | 81277 | 4 | $ - 0 | ||
| 51 | Consult, Outside Slide (Bill Only) | 88321 | 80 | $ - 0 | ||
| 52 | Consult, w/Comp Rvw of His (Bill Only) | 88325 | 62 | $ - 0 | ||
| 53 | Plasma Cell Proliferative Disorder, Pre-Analysis Cell Sorting, Bone Marrow | 88184, 88185x5 | 2 | $ - 0 | ||
| 54 | Consult, w/Slide Prep (Bill Only) | 88323 | 50 | $ - 0 | ||
| 55 | Consult, w/USS Prof (Bill Only) | 88323 | 4 | $ - 0 | ||
| 56 | Decalcification (Bill Only) | 88311 | 28 | $ - 0 | ||
| 57 | EM, Renal Biopsy (Bill Only) | 88348 | 24 | $ - 0 | ||
| 58 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid | 86255x19, 86341 | 2 | $ - 0 | ||
| 59 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum | 86255x19, 86341 | 2 | $ - 0 | ||
| 60 | Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual | 88360x2 | 4 | $ - 0 | ||
| 61 | Hematologic Disorders, DNA Extract and Hold | N/A | 8 | $ - 0 | ||
| 62 | Hematologic Disorders, DNA and RNA Extract and Hold | N/A | 6 | $ - 0 | ||
| 63 | Flow Cytometry Interp, 9-15 Markers | 88188 | 52 | $ - 0 | ||
| 64 | Flow Cytometry Interp, 16 or greater | 88189 | 50 | $ - 0 | ||
| 65 | Flow Cytometry Interp, 2-8 Markers | 88187 | 8 | $ - 0 | ||
| 66 | Flow Cytometry, Cell Surface, First | 88184 | 110 | $ - 0 | ||
| 67 | FLT3 Mutation Analysis, Varies | 81245, 81246 | 4 | $ - 0 | ||
| 68 | Growth Differentiation Factor 15 (GDF15), Plasma | 83520 | 2 | $ - 0 | ||
| 69 | Gadolinium, Urine | 83018 | 2 | $ - 0 | ||
| 70 | Gastrointestinal Dysmotility, Autoimmune/Paraneoplastic Evaluation, Serum | 83519, 86255x6 | 2 | $ - 0 | ||
| 71 | Gastrointestinal Pathogen Panel, PCR, Feces | 87507 | 2 | $ - 0 | ||
| 72 | SpecStain, Frozen (Bill Only) | 88314 | 16 | $ - 0 | ||
| 73 | Helicobacter pylori Culture with Antimicrobial Susceptibilities | 87081 | 2 | $ - 0 | ||
| 74 | 3-Hydroxy-3-Methylglutaryl Coenzyme-A (HMG-CoA) Reductase, Serum | 82397 | 2 | $ - 0 | ||
| 75 | Helicobacter pylori with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Feces | 87798x2 | 4 | $ - 0 | ||
| 76 | Human Papillomavirus (HPV) High/Low Risk, DNA In Situ Hybridization | 88364, 88365 | 4 | $ - 0 | ||
| 77 | IF Additional Stain (Bill Only) | 88350 | 220 | $ - 0 | ||
| 78 | IF Initial Stain (Bill Only) | 88346 | 36 | $ - 0 | ||
| 79 | IHC Multiplex (Bill Only) | 88344 | 2 | $ - 0 | ||
| 80 | IHC Additional Stain (Bill Only) | 88341 | 200 | $ - 0 | ||
| 81 | IHC Initial Stain (Bill Only) | 88342 | 88 | $ - 0 | ||
| 82 | IHC Additional Stain, Tech Only (Bill Only) | 88341 | 66 | $ - 0 | ||
| 83 | IHC Initial Stain, Tech Only (Bill Only) | 88342 | 102 | $ - 0 | ||
| 84 | Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum | 80230 | 60 | $ - 0 | ||
| 85 | Infliximab Antibodies, Serum | 82397 | 36 | $ - 0 | ||
| 86 | Bacterial Identification by Sequencing (Bill Only) | 87798 | 2 | $ - 0 | ||
| 87 | Identification, Next-Generation Sequencing (Bill Only) | 87798 | 6 | $ - 0 | ||
| 88 | ISH Additional Stain (Bill Only) | 88364 | 6 | $ - 0 | ||
| 89 | ISH Initial Stain (Bill Only) | 88365 | 12 | $ - 0 | ||
| 90 | ISH Additional Stain, Tech Only (Bill Only) | 88364 | 2 | $ - 0 | ||
| 91 | ISH Initial Stain, Tech Only (Bill Only) | 88365 | 18 | $ - 0 | ||
| 92 | JAK2 V617F Mutation Detection, Blood | 81270 | 22 | $ - 0 | ||
| 93 | JAK2 Exon 12 and Other Non-V617F Mutation Detection, Blood | 0027U | 2 | $ - 0 | ||
| 94 | Kelch-Like Protein 11 Antibody, Cell Binding Assay, Serum | 86255 | 2 | $ - 0 | ||
| 95 | Level 4 Gross and Microscopic, RB (Bill Only) | 88305 | 20 | $ - 0 | ||
| 96 | M-Protein Isotype by MALDI-TOF Mass Spectrometry, Serum | 0077U | 2 | $ - 0 | ||
| 97 | MayoComplete Melanoma Panel, Next-Generation Sequencing, Tumor | 81445 | 10 | $ - 0 | ||
| 98 | MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor | 81455 | 2 | $ - 0 | ||
| 99 | Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum | 84182, 86255x19, 86341, 86596 | 2 | $ - 0 | ||
| 100 | Susceptibility, Aerobic, MIC | 87186 | 2 | $ - 0 | ||
| 101 | Microdissection, Laser Capture (Bill Only) | 88380 | 6 | $ - 0 | ||
| 102 | Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Ser | 86363 | 2 | $ - 0 | ||
| 103 | MPL Exon 10 Mutation Detection, Reflex | 81339 | 12 | $ - 0 | ||
| 104 | Myeloproliferative Neoplasm (MPN), CALR with Reflex to MPL | 81219 | 2 | $ - 0 | ||
| 105 | MPL Exon 10 Sequencing, Reflex | 81339 | 20 | $ - 0 | ||
| 106 | Mass Spectrometry (Bill Only) | 82542 | 6 | $ - 0 | ||
| 107 | Mycobacterium tuberculosis Complex, Molecular Detection, PCR, Varies | 87556 | 2 | $ - 0 | ||
| 108 | Mycobacterium tuberculosis Complex, Molecular Detection, PCR, FFPE | 87556 | 2 | $ - 0 | ||
| 109 | MYD88 L265P Gene Mutation Analysis | 81305 | 10 | $ - 0 | ||
| 110 | MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next- | 81120, 81121, 81245, 81246, 81352 | 2 | $ - 0 | ||
| 111 | MayoComplete Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing, Varies | 81450 | 10 | $ - 0 | ||
| 112 | Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum | 86053 | 12 | $ - 0 | ||
| 113 | Nuclear Magnetic Resonance (NMR) Lipoprotein Profile, Serum | 83704 | 2 | $ - 0 | ||
| 114 | Orexin-A/Hypocretin-1, Spinal Fluid | 83519 | 2 | $ - 0 | ||
| 115 | Paraneoplastic Autoantibody Evaluation, Serum | 83519, 86255x9, 86596 | 4 | $ - 0 | ||
| 116 | Peripheral Blood (Bill Only) | 85060 | 20 | $ - 0 | ||
| 117 | Peripheral Blood, TC (Bill Only) | 85007 | 30 | $ - 0 | ||
| 118 | Probe, Each Additional (PCPDS) Bill Only | 88271x2, 88274 | 8 | $ - 0 | ||
| 119 | Plasma Cell Proliferative Disorder, High Risk with Reflex Probes, Diagnostic FISH Evaluation, Bone M | 88271x2, 88274, 88291 | 2 | $ - 0 | ||
| 120 | Phospholipase A2 Receptor, Immunofluorescence, Serum | 86255 | 2 | $ - 0 | ||
| 121 | Plasma Cell Proliferative Disorder, FISH, Tissue | Plasma Cell Proliferative Disorder, FISH, Tissue | 2 | $ - 0 | ||
| 122 | Primary Membranous Nephropathy Diagnostic Cascade, Serum | 83520 | 2 | $ - 0 | ||
| 123 | Sarcoma Targeted Gene Fusion/Rearrangement Panels, Next-Generation Sequencing, Tumor | 81479 | 2 | $ - 0 | ||
| 124 | Sickle Solubility, Blood | 85660 | 2 | $ - 0 | ||
| 125 | Slide Review in Molecular Genetics (Bill Only) | 88381 | 19 | $ - 0 | ||
| 126 | Small Lymphocytic Lymphoma, FISH, Tissue | 88377 | 4 | $ - 0 | ||
| 127 | Soluble Fibrin Monomer, Plasma | 85366 | 2 | $ - 0 | ||
| 128 | Programmed Death-Ligand 1 (PD-L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual | 88360 | 6 | $ - 0 | ||
| 129 | SpecStain, Grp I, Microorganisms (Bill Only) | 88312 | 24 | $ - 0 | ||
| 130 | SpecStain, Grp II, Other (Bill Only) | 88313 | 60 | $ - 0 | ||
| 131 | SpecStain, Grp III, Enzyme (Bill Only) | 88319 | 42 | $ - 0 | ||
| 132 | T-Cell Receptor Gene Rearrangement, Bone Marrow | 81340, 81342 | 2 | $ - 0 | ||
| 133 | T-Cell Receptor Gene Rearrangement, Varies | 81340, 81342 | 10 | $ - 0 | ||
| 134 | Thalassemia and Hemoglobinopathy Evaluation, Blood and Serum | 82728, 83020x2, 83021 | 4 | $ - 0 | ||
| 135 | Thrombospondin Type-1 Domain-Containing 7A Antibodies, Serum | 86255 | 2 | $ - 0 | ||
| 136 | Tissue Processing (Bill Only) | 87176 | 2 | $ - 0 | ||
| 137 | Microsatellite Instability, Tumor | 81301 | 2 | $ - 0 | ||
| 138 | Ustekinumab Quantitation with Antibodies, Serum | 80299, 83520 | 28 | $ - 0 | ||
| 139 | Vedolizumab Quantitation with Reflex to Antibodies, Serum | 80280 | 20 | $ - 0 | ||
| 140 | Beta-Globin Cluster Locus Deletion/Duplication, Blood | 81363 | 2 | $ - 0 | ||
| 141 | Beta-Globin Gene Sequencing, Blood | 81364 | 2 | $ - 0 | ||
| 142 | Neuron-Specific Enolase, CSF | 83520 | 18 | $ - 0 | ||
| 143 | Adrenocorticotropic Hormone, Plasma | 82024 | 100 | $ - 0 | ||
| 144 | Ro52 and Ro60 Antibodies, IgG, Serum | 86235x2 | 12 | $ - 0 | ||
| 145 | JAK2 V617F Mutation Detection, Bone Marrow | 81270 | 22 | $ - 0 | ||
| 146 | Vedolizumab Antibodies, Serum | VEMAB | 8 | $ - 0 | ||
| 147 | Myeloproliferative Neoplasm (MPN), JAK2 V617F with reflex to CALR and MPL | 81270 | 20 | $ - 0 | ||
| 148 | KIT Mutation, Exons 8-11 & 17, Hematologic Neoplasms | 81272 | 2 | $ - 0 | ||
| 149 | Total | $ - 0 |
5. Option 4
| CLIN | Service | CPT Code | Estimated Annual Quantity | Base Year Unit Price | Extended Price | Name of Lab Performing Test | Location (City, State) of Lab Performing Test | CLIA Certification Number of Lab Performing Test |
| 1 | Interphases, >=100 (Bill Only) | 88275 | 30 | $ - 0 | ||||
| 2 | Metaphases, 15-20 (Bill Only) | 88262 | 2 | $ - 0 | ||||
| 3 | Metaphases, 20-25 (Bill Only) | 88264 | 36 | $ - 0 | ||||
| 4 | Metaphases, 1-19 (Bill Only) | 88264 | 2 | $ - 0 | ||||
| 5 | Probe, +1 (Bill Only) | 88271 | 2 | $ - 0 | ||||
| 6 | Probe, +2 (Bill Only) | 88271x2 | 26 | $ - 0 | ||||
| 7 | Probe, Each Additional (BLYM) (Bill Only) | 88377 | 2 | $ - 0 | ||||
| 8 | Probe, Each Additional (SLL) (Bill Only) | 88377 | 20 | $ - 0 | ||||
| 9 | Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual | 88360 | 34 | $ - 0 | ||||
| 10 | 25-Hydroxyvitamin D:24,25-Dihydroxyvitamin D Ratio, Serum | 82306, 82542 | 2 | $ - 0 | ||||
| 11 | 3-Methoxytyramine, 24 Hour, Urine | 82542 | 2 | $ - 0 | ||||
| 12 | Thrombophilia Profile, Plasma and Whole Blood | 81240, |
85300, 85303, 85306, 85307, 85379, 85384, 85390, 85610, 85613,
| 85670, 85730 | 2 | $ - 0 | ||||
| 13 | Adalimumab Quantitative with Reflex to Antibody, Serum | 80145 | 74 | $ - 0 | ||
| 14 | Flow Cytometry, Cell Surface, Additional | 88185 | 700 | $ - 0 | ||
| 15 | Adrenocorticotropic Hormone (ACTH), Plasma | 82024 | 370 | $ - 0 | ||
| 16 | Acute Myeloid Leukemia (AML), Specified FISH, Varies | 88271x2, 88275x 88291 | 2 | $ - 0 | ||
| 17 | Adalimumab Antibody, Serum | 83520 | 32 | $ - 0 | ||
| 18 | Amylase, Pancreatic Cyst | 82150 | 10 | $ - 0 | ||
| 19 | Amyloid Protein Identification, Paraffin, LC-MS/MS | 88313 | 6 | $ - 0 | ||
| 20 | APOL1 Genotype, Varies | 81479 | 6 | $ - 0 | ||
| 21 | Alpha-Globin Gene Analysis | 81269 | 2 | $ - 0 | ||
| 22 | Antithrombin Antigen, Plasma | 85301 | 2 | $ - 0 | ||
| 23 | BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR, Quantitative, Monitoring Assay, Varies | 81207 | 2 | $ - 0 | ||
| 24 | BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay | 81206 81208 | 6 | $ - 0 | ||
| 25 | BCR/ABL, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing | 81170 | 2 | $ - 0 | ||
| 26 | B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), Specified FISH, Varies | 88271x2, 88275, 88291 | 2 | $ - 0 | ||
| 27 | Immunoglobulin Gene Rearrangement, Varies | 81261, 81264 | 22 | $ - 0 | ||
| 28 | IGH for B-Cell Chronic Lymphocytic Leukemia (B-CLL), Somatic Hypermutation Analysis | 81263 | 2 | $ - 0 | ||
| 29 | BCR/ABL1, p210, mRNA Detection, RT-PCR, Quantitative, Monitoring Chronic Myelogenous Leukemia (CML) | 81206 | 28 | $ - 0 | ||
| 30 | BCR/ABL1 Qualitative Diagnostic Assay with Reflex | 4 | $ - 0 | |||
| 31 | Biliary Tract Malignancy, FISH | 88377 | 2 | $ - 0 | ||
| 32 | Probe, Each Additional (BLPMF) (Bill Only) | 88271x2, 88275 | 6 | $ - 0 | ||
| 33 | B-Cell Lymphoma, Specified FISH, Varies | 88271x2, 88275x 88291 | 2 | $ - 0 | ||
| 34 | B-Cell Lymphoma, FISH, Tissue | 88377 | 2 | $ - 0 | ||
| 35 | Bone Marrow Aspirate | 85097 | 30 | $ - 0 | ||
| 36 | Bone Marrow Biopsy (Bill Only) | 88305 | 20 | $ - 0 | ||
| 37 | Bone Marrow Clot (Bill Only) | 88305 | 26 | $ - 0 | ||
| 38 | BRAF V600E/V600K Somatic Mutation Analysis, Tumor | 81210 | 2 | $ - 0 | ||
| 39 | Broad Range Bacterial PCR and Sequencing | 87801 | 8 | $ - 0 | ||
| 40 | CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN), Reflex | 81219 | 12 | $ - 0 | ||
| 41 | Comprehensive Cardiomyopathy Multi-Gene Panel, Blood | 81439 | 2 | $ - 0 | ||
| 42 | Clostridium difficile Culture | 87081 | 2 | $ - 0 | ||
| 43 | Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid | 82378 | 10 | $ - 0 | ||
| 44 | Chromogranin A, Serum | 86316 | 130 | $ - 0 | ||
| 45 | Chromosome Analysis, Hematologic Disorders, Bone Marrow | 88237, 88291 | 40 | $ - 0 | ||
| 46 | Chromosome Analysis, Congenital Disorders, Blood | 88230, 88291 | 2 | $ - 0 | ||
| 47 | Cutaneous Direct IFA, Biopsy | 88346, 8835x5 | 2 | $ - 0 | ||
| 48 | Coccidioides, Rapid PCR | 87798 | 2 | $ - 0 | ||
| 49 | Chronic Lymphocytic Leukemia (CLL), Diagnostic FISH, Varies | 88271x12, 88275x6, 88291 | 2 | $ - 0 | ||
| 50 | Chromosomal Microarray, Hematologic Disorders | 81277 | 4 | $ - 0 | ||
| 51 | Consult, Outside Slide (Bill Only) | 88321 | 80 | $ - 0 | ||
| 52 | Consult, w/Comp Rvw of His (Bill Only) | 88325 | 62 | $ - 0 | ||
| 53 | Plasma Cell Proliferative Disorder, Pre-Analysis Cell Sorting, Bone Marrow | 88184, 88185x5 | 2 | $ - 0 | ||
| 54 | Consult, w/Slide Prep (Bill Only) | 88323 | 50 | $ - 0 | ||
| 55 | Consult, w/USS Prof (Bill Only) | 88323 | 4 | $ - 0 | ||
| 56 | Decalcification (Bill Only) | 88311 | 28 | $ - 0 | ||
| 57 | EM, Renal Biopsy (Bill Only) | 88348 | 24 | $ - 0 | ||
| 58 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid | 86255x19, 86341 | 2 | $ - 0 | ||
| 59 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum | 86255x19, 86341 | 2 | $ - 0 | ||
| 60 | Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual | 88360x2 | 4 | $ - 0 | ||
| 61 | Hematologic Disorders, DNA Extract and Hold | N/A | 8 | $ - 0 | ||
| 62 | Hematologic Disorders, DNA and RNA Extract and Hold | N/A | 6 | $ - 0 | ||
| 63 | Flow Cytometry Interp, 9-15 Markers | 88188 | 52 | $ - 0 | ||
| 64 | Flow Cytometry Interp, 16 or greater | 88189 | 50 | $ - 0 | ||
| 65 | Flow Cytometry Interp, 2-8 Markers | 88187 | 8 | $ - 0 | ||
| 66 | Flow Cytometry, Cell Surface, First | 88184 | 110 | $ - 0 | ||
| 67 | FLT3 Mutation Analysis, Varies | 81245, 81246 | 4 | $ - 0 | ||
| 68 | Growth Differentiation Factor 15 (GDF15), Plasma | 83520 | 2 | $ - 0 | ||
| 69 | Gadolinium, Urine | 83018 | 2 | $ - 0 | ||
| 70 | Gastrointestinal Dysmotility, Autoimmune/Paraneoplastic Evaluation, Serum | 83519, 86255x6 | 2 | $ - 0 | ||
| 71 | Gastrointestinal Pathogen Panel, PCR, Feces | 87507 | 2 | $ - 0 | ||
| 72 | SpecStain, Frozen (Bill Only) | 88314 | 16 | $ - 0 | ||
| 73 | Helicobacter pylori Culture with Antimicrobial Susceptibilities | 87081 | 2 | $ - 0 | ||
| 74 | 3-Hydroxy-3-Methylglutaryl Coenzyme-A (HMG-CoA) Reductase, Serum | 82397 | 2 | $ - 0 | ||
| 75 | Helicobacter pylori with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Feces | 87798x2 | 4 | $ - 0 | ||
| 76 | Human Papillomavirus (HPV) High/Low Risk, DNA In Situ Hybridization | 88364, 88365 | 4 | $ - 0 | ||
| 77 | IF Additional Stain (Bill Only) | 88350 | 220 | $ - 0 | ||
| 78 | IF Initial Stain (Bill Only) | 88346 | 36 | $ - 0 | ||
| 79 | IHC Multiplex (Bill Only) | 88344 | 2 | $ - 0 | ||
| 80 | IHC Additional Stain (Bill Only) | 88341 | 200 | $ - 0 | ||
| 81 | IHC Initial Stain (Bill Only) | 88342 | 88 | $ - 0 | ||
| 82 | IHC Additional Stain, Tech Only (Bill Only) | 88341 | 66 | $ - 0 | ||
| 83 | IHC Initial Stain, Tech Only (Bill Only) | 88342 | 102 | $ - 0 | ||
| 84 | Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum | 80230 | 60 | $ - 0 | ||
| 85 | Infliximab Antibodies, Serum | 82397 | 36 | $ - 0 | ||
| 86 | Bacterial Identification by Sequencing (Bill Only) | 87798 | 2 | $ - 0 | ||
| 87 | Identification, Next-Generation Sequencing (Bill Only) | 87798 | 6 | $ - 0 | ||
| 88 | ISH Additional Stain (Bill Only) | 88364 | 6 | $ - 0 | ||
| 89 | ISH Initial Stain (Bill Only) | 88365 | 12 | $ - 0 | ||
| 90 | ISH Additional Stain, Tech Only (Bill Only) | 88364 | 2 | $ - 0 | ||
| 91 | ISH Initial Stain, Tech Only (Bill Only) | 88365 | 18 | $ - 0 | ||
| 92 | JAK2 V617F Mutation Detection, Blood | 81270 | 22 | $ - 0 | ||
| 93 | JAK2 Exon 12 and Other Non-V617F Mutation Detection, Blood | 0027U | 2 | $ - 0 | ||
| 94 | Kelch-Like Protein 11 Antibody, Cell Binding Assay, Serum | 86255 | 2 | $ - 0 | ||
| 95 | Level 4 Gross and Microscopic, RB (Bill Only) | 88305 | 20 | $ - 0 | ||
| 96 | M-Protein Isotype by MALDI-TOF Mass Spectrometry, Serum | 0077U | 2 | $ - 0 | ||
| 97 | MayoComplete Melanoma Panel, Next-Generation Sequencing, Tumor | 81445 | 10 | $ - 0 | ||
| 98 | MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor | 81455 | 2 | $ - 0 | ||
| 99 | Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum | 84182, 86255x19, 86341, 86596 | 2 | $ - 0 | ||
| 100 | Susceptibility, Aerobic, MIC | 87186 | 2 | $ - 0 | ||
| 101 | Microdissection, Laser Capture (Bill Only) | 88380 | 6 | $ - 0 | ||
| 102 | Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Ser | 86363 | 2 | $ - 0 | ||
| 103 | MPL Exon 10 Mutation Detection, Reflex | 81339 | 12 | $ - 0 | ||
| 104 | Myeloproliferative Neoplasm (MPN), CALR with Reflex to MPL | 81219 | 2 | $ - 0 | ||
| 105 | MPL Exon 10 Sequencing, Reflex | 81339 | 20 | $ - 0 | ||
| 106 | Mass Spectrometry (Bill Only) | 82542 | 6 | $ - 0 | ||
| 107 | Mycobacterium tuberculosis Complex, Molecular Detection, PCR, Varies | 87556 | 2 | $ - 0 | ||
| 108 | Mycobacterium tuberculosis Complex, Molecular Detection, PCR, FFPE | 87556 | 2 | $ - 0 | ||
| 109 | MYD88 L265P Gene Mutation Analysis | 81305 | 10 | $ - 0 | ||
| 110 | MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next- | 81120, 81121, 81245, 81246, 81352 | 2 | $ - 0 |
This is the start of the file's text. The full file is on GovTribe.
File details come from the government source that posted it. Updated .